<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-27409" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Polyglandular Autoimmune Syndrome Type II</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Singh</surname>
            <given-names>Gurdeep</given-names>
          </name>
          <aff>Our Lady of Lourdes Memorial Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jialal</surname>
            <given-names>Ishwarlal</given-names>
          </name>
          <aff>VA MEDICAL CENTER, MATHER , CA</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Gurdeep Singh declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ishwarlal Jialal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-27409.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Polyglandular autoimmune syndrome type 2 (PAS-2) is an autoimmune syndrome which leads to lymphocytic infiltration causing organ-specific damage. PAS-2 is diagnosed when at least 2 out of 3 of the following are present: primary adrenal insufficiency (Addison disease), autoimmune thyroid disease-causing Grave's disease or hypothyroidism, and type 1 diabetes mellitus (T1DM). Carpenter syndrome is a type of PAS-2 that includes the triad of Addison disease, autoimmune thyroid disease, and T1DM. This activity reviews the diagnosis and management of the Carpenter syndrome variant of PAS-2 and highlights the role of the interprofessional team in the early detection and management of this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Distinguish Carpenter's syndrome from other types of polyglandular autoimmune syndrome type 2.</p></list-item><list-item><p>Explain signs and symptoms that should prompt consideration of polyglandular autoimmune syndrome type 2.</p></list-item><list-item><p>Describe the management of Carpenter's syndrome.</p></list-item><list-item><p>Explain how coordination of interprofessional teams can lead to earlier diagnosis of polyglandular autoimmune syndrome type 2, allowing for treatment aimed at minimizing comorbidities, leading to better patient outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27409&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27409">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-27409.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Polyglandular autoimmune&#x000a0;syndrome (PAS) is a clustering of at least 2 or more endocrine diseases in a single patient. Common autoimmune polyglandular syndromes are PAS-1, PAS-2 and X-linked immune dysregulation polyendocrinopathy and enteropathy (IPEX).<xref ref-type="bibr" rid="article-27409.r1">[1]</xref>&#x000a0;Recently, a&#x000a0;new category has emerged. It is iatrogenic polyendocrinopathy due to use of immunoregulatory agents in patients with cancer.<xref ref-type="bibr" rid="article-27409.r2">[2]</xref>&#x000a0;Ipilimumab which is used to treat metastatic cancer can cause hypophysitis. Polyglandular autoimmune&#x000a0;syndrome type 2 (PAS-2)&#x000a0;is an autoimmune disease with polygenic inheritance. It is also called Schmidt syndrome and Carpenter syndrome. The clustering of multiple endocrine diseases in a single patient was documented well before the classification of PAS came into existence. In 1926, Schmidt published 2 cases of Addison disease and chronic lymphocytic thyroiditis known as Schmidt syndrome.<xref ref-type="bibr" rid="article-27409.r3">[3]</xref>&#x000a0;Five years later, in 1931, Rowntree and Snell reported the first case of Addison disease with hyperthyroidism and type 1 diabetes mellitus (T1DM).<xref ref-type="bibr" rid="article-27409.r3">[3]</xref>. Beaven et al. reviewed 66 cases, and Solomon et al. reviewed 113 cases of Addison disease and diabetes mellitus.<xref ref-type="bibr" rid="article-27409.r3">[3]</xref>&#x000a0;Post-mortem investigation showed lymphocytic infiltration in the glands in the majority of these cases, confirming that&#x000a0;it was an autoimmune disease. Carpenter confirmed the association of diabetes mellitus with Schmidt syndrome in a review of 142 cases of Schmidt syndrome and coined the term Carpenter syndrome, which is a triad of Addison disease, autoimmune thyroid disease, and TIDM.<xref ref-type="bibr" rid="article-27409.r4">[4]</xref>&#x000a0;This review focuses on the diagnosis and management of PAS-2 defined by the cluster of T1DM, auto-immune thyroid disease, and Addison disease.</p>
      </sec>
      <sec id="article-27409.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>PAS-2 is an autoimmune disease affecting multiple endocrine organs.</p>
        <p>PAS-2 is a polygenic disease, with significant heterogeneity due to multiple genetic loci and environmental factors responsible for the organ-specific damage. Major histocompatibility complex&#x000a0;<italic toggle="yes">(MHC)</italic>&#x000a0;genes located on chromosome 6 have been implicated in organ-specific damage in PAS-2.[1] It appears that HLA-DR3 and&#x000a0;HLA-DR4 haplotypes and the class 2 HLA alleles DQ2 and DQ8 increase predisposition to PAS-2.<xref ref-type="bibr" rid="article-27409.r2">[2]</xref><xref ref-type="bibr" rid="article-27409.r4">[4]</xref></p>
        <p>Non-HLA genes can also predispose to PAS-2 and include CD25-interleukin-2 receptor, cytotoxic T-lymphocyte protein 4 (CTLA-4), and protein tyrosine-protein phosphatase, non-receptor type 22 (PTPN22).<xref ref-type="bibr" rid="article-27409.r1">[1]</xref></p>
      </sec>
      <sec id="article-27409.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>PAS-2 is the commonest PAS. There is significant variability in reported prevalence ranging from 1:1000 to 1:20,000 in the general population.<xref ref-type="bibr" rid="article-27409.r1">[1]</xref>&#x000a0;It is around 3 times more common in women.<xref ref-type="bibr" rid="article-27409.r5">[5]</xref>&#x000a0;Typical age of onset is between 20 to 40 years.[2]</p>
      </sec>
      <sec id="article-27409.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Polyglandular autoimmune&#x000a0;syndrome type 2 is an autoimmune syndrome which leads to lymphocytic infiltration causing organ-specific damage.</p>
      </sec>
      <sec id="article-27409.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The diagnosis of PAS-2&#x000a0;&#x000a0;is often delayed, and this can sometimes cause significant complications. Usually, these patients present with isolated endocrine dysfunction and later develop other endocrine and non-endocrine diseases.</p>
        <p>Manuela Dittmar et al. followed 151 out of 360 PAS-2&#x000a0;&#x000a0;patients for 13 years and found that autoimmune thyroid disease was most prevalent in 99 patients (65.6%), and out of these, 50 patients (33.1%) were found to have Graves' disease, and 49 patients (32.5%) had Hashimoto&#x02019;s thyroiditis. T1DM was found in 92 patients (60.9%), and Addison disease was found in 28 patients (18.5%). T1DM &#x000a0;occurred early in life with a mean age 27.5 years while other diseases manifested around age 36.5 to 40 years. The coexistence of T1DM &#x000a0;and thyroid disease was most common while the coexistence of Addison and thyroid disease was less common.<xref ref-type="bibr" rid="article-27409.r6">[6]</xref></p>
        <p>PAS-2 patients may present with vague symptoms of weight loss, fatigue, nausea, vomiting, generalized weakness, anorexia, abdominal pain, diarrhea, polyuria, and polydipsia. Common signs in these patients may include mucosal and cutaneous hyperpigmentation low blood glucose levels and orthostatic hypotension if Addison disease is the diagnosis or polyuria and polydipsia with hyperglycemia if T1DM is present. Hypothyroidism can present with bradycardia, and delayed tendon reflexes.</p>
        <p>Patients with Addison disease may present with shock-like features including hypotension, tachycardia, and altered mental status suggestive of adrenal crisis.</p>
        <p>There is a 2.5-fold increase risk of adrenal crisis in patients who have Addison disease due to the autoimmune polyendocrine syndrome.<xref ref-type="bibr" rid="article-27409.r7">[7]</xref></p>
      </sec>
      <sec id="article-27409.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>PAS-2&#x000a0;&#x000a0;is diagnosed by occurrence in the same patient of at least 2 out of 3 manifestations including primary adrenal insufficiency (Addison disease), autoimmune thyroid disease-causing Grave disease or hypothyroidism and T1DM. Other endocrine and non-endocrine manifestations of PAS-2&#x000a0;&#x000a0;are primary hypogonadism, myasthenia gravis and celiac disease, alopecia, vitiligo, pernicious anemia, idiopathic heart block, Stiff-man syndrome, Parkinson disease, IgA deficiency, serositis, dermatitis herpetiformis, idiopathic thrombocytopenia, and hypophysitis.[1][2]<xref ref-type="bibr" rid="article-27409.r8">[8]</xref></p>
        <p>Diagnosis of Addison disease or primary adrenal insufficiency is based on a &#x000a0;morning serum cortisol level less than 6.0 mcg/dl or a serum cortisol less than 18 mcg/dl at 60 minutes after ACTH stimulation test using 250-mcg intravenous or intramuscular bolus of cosyntropin.[6] The presence of 21-hydroxylase or 17-hydroxylase autoantibodies can confirm autoimmune adrenalitis.<xref ref-type="bibr" rid="article-27409.r9">[9]</xref>&#x000a0;Patients with positive 21-hydroxylase&#x000a0;or 17-hydroxylase antibodies should have annual monitoring of morning cortisol and ACTH and cosyntropin stimulation test if suspicion is high.</p>
        <p>Diagnosis of hypothyroidism due to Hashimoto&#x02019;s thyroiditis or hyperthyroidism due to Graves' disease can be made by evaluation of TSH and T4 for the former and TSH, T4, and T3 for the latter. In euthyroid patients, the presence of anti-thyroglobulin antibodies, thyroid microsomal antibodies and thyrotropin receptor antibodies (Graves' disease) can detect patients at risk of thyroid disease in the future.</p>
        <p>Diagnosis of T1DM can be made with classic symptoms of polyuria, polydipsia, and polyphagia associated with elevated serum glucose level (fasting greater than 125 mg/dl and random over 200 mg/dl and or elevated HbA1c, greater than 6.4%). Standard guidelines should be used for the diagnosis of individual organ dysfunction. These patients can be tested for anti-glutamic acid decarboxylase antibodies (GAD), anti-islet cell antigen 2 and anti-Zn transporter 8 antibodies. Also following a challenge with glucagon (1 mg) the plasma C-Peptide is less than 0.6 ng/ml.</p>
        <p>A timely diagnosis of PAS-2&#x000a0;&#x000a0;requires knowledge of the complete spectrum of this disease. A complete history and thorough physical exam may give important clues. In many cases, the diagnosis of PAS-2&#x000a0;&#x000a0;may be delayed due to the heterogeneous presentation. It is uncommon for these patients to have dysfunction of all 3 major endocrine organs simultaneously and there is usually a latent phase between the endocrinopathies.</p>
        <p>Patients with PAS-2&#x000a0;&#x000a0;and their family members should be monitored long-term due to the risk of development of organ-specific dysfunction&#x000a0;over time. Family members who are not affected with PAS-2 should watch for symptoms related to adrenal, thyroid and endocrine pancreatic dysfunction. Asymptomatic carriers should be followed on an annual basis.[1]</p>
        <p>Organ-specific antibodies like 21-hydroxylase antibody for Addison disease, an antibody against GAD 65 for type 1 diabetes, thyrotropin receptor antibody, and TPO antibody for autoimmune thyroid disease can be assayed for making a diagnosis. Transglutaminase antibodies are useful for the diagnosis of Celiac disease. However, the presence of&#x000a0;autoantibodies to thyroid, adrenal, and islets does not predict glandular failure.</p>
        <p>PAS-2&#x000a0;&#x000a0;can be differentiated from PAS-1 due to late-onset on clinical manifestation mostly after age 20, different patterns of disease combination with no mucocutaneous candidiasis, and polygenic inheritance versus monogenic.</p>
        <p>Delay in diagnosis can cause significant morbidity and mortality in these patients due to the risk of severe hypothyroidism, adrenal crisis, and diabetic ketoacidosis.</p>
        <p>Thyroid ultrasound is an excellent noninvasive tool to evaluate thyroid disease. The diffuse or multifocal hypoechoic pattern is commonly seen in autoimmune thyroid disease.</p>
        <p>CT scan and MRI of the adrenal gland is often normal, but sometimes there is a decrease in the volume of the gland suggestive of atrophy.</p>
        <p>Unfortunately, there is no reliable imaging technique which can indicate endocrine pancreatic disease.</p>
      </sec>
      <sec id="article-27409.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Replacement with appropriate&#x000a0;hormones is the key. These patients should be followed up by an interprofessional team lead by an endocrinologist. Patients should be followed at least every 6 months with appropriate&#x000a0;blood work to avoid over and under-treatment. These patients are at risk of adrenal crisis, hypoglycemia, diabetic ketoacidosis, among others. The treating physician should be proactive to diagnose these conditions and possible&#x000a0;manifestations expected to occur over time without delay to avoid complications.</p>
        <p>Care should be taken to treat patients with thyroxine as this can precipitate life-threatening Addisonian crisis if the patient has undiagnosed adrenal insufficiency. In these patients,&#x000a0;testing for adrenal insufficiency should be done before treating hypothyroidism with levothyroxine.<xref ref-type="bibr" rid="article-27409.r10">[10]</xref>&#x000a0;Hydrocortisone replacement should precede thyroxine therapy by about a week.</p>
        <p>Family members at risk for developing PAS-2 can be&#x000a0;identified by checking organ-specific antibodies.</p>
        <p>Due to the autoimmune nature of this disease, multiple immunosuppressants and immune-modulators have been tested, but none of these agents are being used on a regular basis due to the potential risk of side effects.</p>
      </sec>
      <sec id="article-27409.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Adrenal crisis&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Celiac disease</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Chronic pancreatitis&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>DiGeorge syndrome&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hemochromatosis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hypoglycemia</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hyponatremia</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hypothyroidism&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Macrocytosis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Septic shock&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27409.s10" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Patients affected with PAS-2 can face multiple challenges and may feel a significant burden due to the complexity of this disease. An interprofessional team approach for care and follow up of PAS-2 patients should be used because of the involvement of multiple endocrine and non-endocrine organs, and this team should be led by an endocrinologist. Interprofessional communications between different physicians taking care of the PAS-2 patient can be significantly improved by involving a case coordinator who can improve the quality of care. This can also&#x000a0;prevent overtreatment and undertreatment.&#x000a0;Treatment of autoimmune polyendocrine syndrome in an interprofessional setting can improve outcomes.<xref ref-type="bibr" rid="article-27409.r11">[11]</xref>&#x000a0;(Level III)</p>
      </sec>
      <sec id="article-27409.s11">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27409&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27409">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/hormones-and-body-chemistry/polyglandular-autoimmune-syndrome-type-ii/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=27409">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/27409/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=27409">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-27409.s12">
        <title>References</title>
        <ref id="article-27409.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Husebye</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>K&#x000e4;mpe</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Autoimmune Polyendocrine Syndromes.</article-title>
            <source>N Engl J Med</source>
            <year>2018</year>
            <month>Mar</month>
            <day>22</day>
            <volume>378</volume>
            <issue>12</issue>
            <fpage>1132</fpage>
            <page-range>1132-1141</page-range>
            <pub-id pub-id-type="pmid">29562162</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27409.r2">
          <label>2</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Sperling</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Angelousi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yau</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <chapter-title>Autoimmune Polyglandular Syndromes</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Feingold</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Anawalt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Blackman</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Boyce</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chrousos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Corpas</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>de Herder</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Dhatariya</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dungan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hofland</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kalra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kaltsas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kapoor</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Koch</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kopp</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Korbonits</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kovacs</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Kuohung</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Laferr&#x000e8;re</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McGee</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>McLachlan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>New</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Purnell</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sahay</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Singer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sperling</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Stratakis</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Trence</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>DP</given-names>
              </name>
            </person-group>
            <source>Endotext [Internet]</source>
            <publisher-name>MDText.com, Inc.</publisher-name>
            <publisher-loc>South Dartmouth (MA)</publisher-loc>
            <year>2024</year>
            <month>7</month>
            <day>21</day>
            <pub-id pub-id-type="pmid">25905375</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27409.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Betterle</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lazzarotto</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Presotto</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Autoimmune polyglandular syndrome Type 2: the tip of an iceberg?</article-title>
            <source>Clin Exp Immunol</source>
            <year>2004</year>
            <month>Aug</month>
            <volume>137</volume>
            <issue>2</issue>
            <fpage>225</fpage>
            <page-range>225-33</page-range>
            <pub-id pub-id-type="pmid">15270837</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27409.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>CARPENTER</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>SOLOMON</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>SILVERBERG</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>BLEDSOE</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>NORTHCUTT</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>KLINENBERG</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>BENNETT</surname>
                <given-names>IL</given-names>
              </name>
              <name>
                <surname>HARVEY</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>SCHMIDT'S SYNDROME (THYROID AND ADRENAL INSUFFICIENCY). A REVIEW OF THE LITERATURE AND A REPORT OF FIFTEEN NEW CASES INCLUDING TEN INSTANCES OF COEXISTENT DIABETES MELLITUS.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>1964</year>
            <month>Mar</month>
            <volume>43</volume>
            <fpage>153</fpage>
            <page-range>153-80</page-range>
            <pub-id pub-id-type="pmid">14132718</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27409.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>F&#x000f6;rster</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Krummenauer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>K&#x000fc;hn</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Beyer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kahaly</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>[Polyglandular autoimmune syndrome type II: epidemiology and forms of manifestation].</article-title>
            <source>Dtsch Med Wochenschr</source>
            <year>1999</year>
            <month>Dec</month>
            <day>10</day>
            <volume>124</volume>
            <issue>49</issue>
            <fpage>1476</fpage>
            <page-range>1476-81</page-range>
            <pub-id pub-id-type="pmid">10629665</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27409.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dittmar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kahaly</surname>
                <given-names>GJ</given-names>
              </name>
            </person-group>
            <article-title>Polyglandular autoimmune syndromes: immunogenetics and long-term follow-up.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2003</year>
            <month>Jul</month>
            <volume>88</volume>
            <issue>7</issue>
            <fpage>2983</fpage>
            <page-range>2983-92</page-range>
            <pub-id pub-id-type="pmid">12843130</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27409.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meyer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Badenhoop</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Linder</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Addison's disease with polyglandular autoimmunity carries a more than 2&#x000b7;5-fold risk for adrenal crises: German Health insurance data 2010-2013.</article-title>
            <source>Clin Endocrinol (Oxf)</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>85</volume>
            <issue>3</issue>
            <fpage>347</fpage>
            <page-range>347-53</page-range>
            <pub-id pub-id-type="pmid">26896640</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27409.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cutolo</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Autoimmune polyendocrine syndromes.</article-title>
            <source>Autoimmun Rev</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>85</fpage>
            <page-range>85-9</page-range>
            <pub-id pub-id-type="pmid">24055063</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27409.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brand&#x000e3;o Neto</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>de Carvalho</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and classification of Addison's disease (autoimmune adrenalitis).</article-title>
            <source>Autoimmun Rev</source>
            <year>2014</year>
            <season>Apr-May</season>
            <volume>13</volume>
            <issue>4-5</issue>
            <fpage>408</fpage>
            <page-range>408-11</page-range>
            <pub-id pub-id-type="pmid">24424183</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27409.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Ping</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Qi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Xiao</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Delayed diagnosis with autoimmune polyglandular syndrome type 2 causing acute adrenal crisis: A case report.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>95</volume>
            <issue>42</issue>
            <fpage>e5062</fpage>
            <pub-id pub-id-type="pmid">27759634</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27409.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gouda</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Al-Amin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Grabsch</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Donnellan</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>A multidisciplinary approach to management of autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED).</article-title>
            <source>BMJ Case Rep</source>
            <year>2013</year>
            <month>Jan</month>
            <day>30</day>
            <volume>2013</volume>
            <pub-id pub-id-type="pmid">23370953</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
